Marksans Pharma, incorporated in 1992, was a wholly-owned subsidiary of Glenmark Pharmaceuticals. It became a separate entity in March 2003 and the name was changed to Marksans Pharma in 2005.

Currently the company has presence in Active Pharmaceuticals Ingredients (APIs), formulations and biopharmaceuticals. It is also actively engaged in research and development and offers contract research and manufacturing services (CRAMS) to global pharmaceutical companies.

The company, engaged in production of prescription drugs, caters in areas like oncology, gastroenterology, antidiabetic, cardiovascular, pain management, gynaecology and others.

The company's plants have been built as per USFDA guidelines and have received approval from various health authorities namely TGA (Australia), MHRA (United Kingdom) ANVISA (Brazil) apart from WHO GMP certificate.

Marksans Pharma  acquired Relonchem, a leading UK-based generic pharmaceutical company. This acquisition gave company an immediate sales and marketing front-end access to the highly regulated and lucrative generic medicines market in UK and Europe.

Marksans Pharma exports its products to markets in Europe, Latin America, Africa and Oceania.

In 2010 Company entered into a Business Transfer Agreement with Kores (India) Limited

Business area

Research and Development- The company’s R&D centre is situated in Goa and is engaged in new drug discovery chemistry, pharmacokinetics, pharmacology/ molecular biology, toxicology, and related skills and support areas.

Marksans Pharma Ltd.

Jubilant Pharmova Ltd.

Glenmark Life Sciences Ltd.

Neuland Laboratories Ltd.

FDC Ltd.

Procter & Gamble Health Ltd.

Medplus Health Services Ltd.

Caplin Point Laboratories Ltd.

Granules India Ltd.

Wockhardt Ltd.

Strides Pharma Science Ltd.

Aarti Drugs Ltd.

AMI Organics Ltd.

Advanced Enzyme Technologies Ltd.

Indoco Remedies Ltd.

Open Price	161.15	Volume	592
Prev. Close	161.15

Performance